ATAI Life Sciences NV Total Liabilities
ATAI Life Sciences NV total liabilities. Based on the latest financial reports, ATAI Life Sciences NV (9VC) has total liabilities worth €79.91 Million EUR (≈ $93.43 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 9VC asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ATAI Life Sciences NV (2019–2024)
Total liabilities of ATAI Life Sciences NV from 2019 to 2024. This chart illustrates how ATAI Life Sciences NV's total liabilities have evolved over time, based on quarterly financial data. Explore ATAI Life Sciences NV strategic investment ratio to see how much of total assets are deployed in long-term investments.
ATAI Life Sciences NV Competitors by Total Liabilities
The table below lists competitors of ATAI Life Sciences NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
REX American Resources Corporation
NYSE:REX
|
USA | $83.92 Million |
|
MilDef Group AB
ST:MILDEF
|
Sweden | Skr1.53 Billion |
|
Aygaz AS
IS:AYGAZ
|
Turkey | TL12.66 Billion |
|
Del Monte Corporation
NYSE:DMC
|
USA | $1.36 Billion |
|
Edelweiss Financial Services Limited
NSE:EDELWEISS
|
India | Rs377.98 Billion |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
China | CN¥1.14 Billion |
|
Orezone Gold Corp
TO:ORE
|
Canada | CA$739.50 Million |
|
Shanghai Luxin Packing Materials Science&Technology Co Ltd
SHE:002565
|
China | CN¥589.25 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down ATAI Life Sciences NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ATAI Life Sciences NV (9VC) total assets.
Liquidity & Leverage Metrics
ATAI Life Sciences NV Total Liabilities Ratios Explained
ATAI Life Sciences NV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ATAI Life Sciences NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ATAI Life Sciences NV (2019–2024)
The table below shows the annual total liabilities of ATAI Life Sciences NV from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €42.83 Million ≈ $50.08 Million |
-12.87% |
| 2023-12-31 | €49.16 Million ≈ $57.48 Million |
+23.91% |
| 2022-12-31 | €39.67 Million ≈ $46.38 Million |
+40.66% |
| 2021-12-31 | €28.21 Million ≈ $32.98 Million |
+74.33% |
| 2020-12-31 | €16.18 Million ≈ $18.92 Million |
+552.95% |
| 2019-12-31 | €2.48 Million ≈ $2.90 Million |
-- |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more